Literature DB >> 2038748

Early indications of monocrotaline pyrrole-induced lung injury in rats.

A E Schultze1, J G Wagner, S M White, R A Roth.   

Abstract

Monocrotaline pyrrole (MCTP), a putative metabolite of the naturally occurring plant toxin, monocrotaline (MCT), causes lung injury, pulmonary hypertension, and right cardioventricular hypertrophy when administered intravenously to rats. The lesions caused by MCTP administration are similar to those caused by MCT but appear to occur on a slightly accelerated time course. To explore the onset and development of lung lesions, male Sprague-Dawley rats were treated with a single, intravenous injection of MCTP, and several markers of lung injury were evaluated at early times after administration. Rats received 3.5 mg MCTP/kg or an equal volume of the vehicle, N,N-dimethylformamide (DMF), via the tail vein at time 0 and were killed at 4, 12, 24, 48, 72, or 120 hr after treatment. Beginning at 4 hr, MCTP-treated rats had increased wet lung-to-body-weight ratios (LW/BW). The LW/BW remained elevated at 12 hr, returned to baseline at 24 hr, then increased steadily over the next few days. At 24 hr, the protein concentration of cell-free bronchoalveolar lavage fluid (BALF) was slightly elevated. Lactate dehydrogenase activity in cell-free BALF samples was moderately increased 48 hr after MCTP. Changes in these markers were modest initially but became much more pronounced by 120 hr. Total nucleated cell counts in BALF were variable but were moderately elevated at 120 hr. Cytologic examination of the BALF samples revealed small but significant infiltrates of segmented neutrophils at 4 hr and relatively large infiltrates of segmented neutrophils and small lymphocytes at 120 hr post-treatment. Mature neutrophils had degenerate cytomorphologic characteristics at both 4 and 120 hr. These results confirm that pronounced lung injury is delayed for several days after a single, intravenous administration of MCTP, but they also indicate that subtle lung injury can be detected using quantitative markers quite early after MCTP administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038748     DOI: 10.1016/0041-008x(91)90189-l

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  10 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Mol Cell Biochem       Date:  1995-01-12       Impact factor: 3.396

3.  Cyclophosphamide induced early biochemical changes in lung lavage fluid and alterations in lavage cell function.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Lung       Date:  1994       Impact factor: 2.584

4.  Effects of antibacterial agents on in vitro ovine ruminal biotransformation of the hepatotoxic pyrrolizidine alkaloid jacobine.

Authors:  D E Wachenheim; L L Blythe; A M Craig
Journal:  Appl Environ Microbiol       Date:  1992-08       Impact factor: 4.792

5.  Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry.

Authors:  Chun Zhou; Mary I Townsley; Mikhail Alexeyev; Norbert F Voelkel; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-15       Impact factor: 5.464

6.  Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats.

Authors:  M Y Farhat; M F Chen; T Bhatti; A Iqbal; S Cathapermal; P W Ramwell
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 7.  Redox Regulation, Oxidative Stress, and Inflammation in Group 3 Pulmonary Hypertension.

Authors:  Olena Rudyk; Philip I Aaronson
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Rodent models of cardiopulmonary disease: their potential applicability in studies of air pollutant susceptibility.

Authors:  U P Kodavanti; D L Costa; P A Bromberg
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

Review 9.  The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension.

Authors:  Shalina Taylor; Omar Dirir; Roham T Zamanian; Marlene Rabinovitch; A A Roger Thompson
Journal:  Front Med (Lausanne)       Date:  2018-08-03

Review 10.  Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective.

Authors:  Thomas Koudstaal; Karin A Boomars; Mirjam Kool
Journal:  J Clin Med       Date:  2020-02-19       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.